{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:55:38Z","timestamp":1789016138901,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Onconova Therapeutics, Inc"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.leukres.2020.106369","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T21:25:11Z","timestamp":1589232311000},"page":"106369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study"],"prefix":"10.1016","volume":"94","author":[{"given":"Shyamala C.","family":"Navada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"OdchimarReissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro N.","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosmy B.","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin P.","family":"Demakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Zbyszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Woodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Fruchtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis R.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2020.106369_bib0005","series-title":"NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes, Version 2","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"10.1016\/j.leukres.2020.106369_bib0010","series-title":"Cancer Medicine","first-page":"1529","article-title":"The myelodysplastic syndrome; Chapter 113","author":"Silverman","year":"2017"},{"issue":"10","key":"10.1016\/j.leukres.2020.106369_bib0015","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2020.106369_bib0020","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.leukres.2020.106369_bib0025","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.leukres.2020.106369_bib0030","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2020.106369_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106369_bib0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106369_bib0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-na\u00efve, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106369_bib0050","first-page":"1","article-title":"Acute myeloid leukemia in the older adults","volume":"6","author":"Almeida","year":"2016","journal-title":"Leuk. Res. Rep."},{"issue":"18","key":"10.1016\/j.leukres.2020.106369_bib0055","doi-asserted-by":"crossref","first-page":"6254","DOI":"10.1021\/jm200570p","article-title":"Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-(2-methoxy-5-[(2\u2019,4\u2019,6\u2019-trimethoxystyrylsulfonyl) methyl] phenylamino) acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity","volume":"54","author":"Reddy","year":"2011","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.leukres.2020.106369_bib0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2016.03.045","article-title":"A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling","volume":"165","author":"Athuluri-Divakur","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2020.106369_bib0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomized, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2020.106369_bib0070","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood.V114.22.3827.3827","article-title":"Single cell network profiling (SCNP) to evaluate the mechanism of action of ON 01910.Na, a novel clinical trial stage compound","volume":"114","author":"Soper","year":"2009","journal-title":"Blood"},{"issue":"309","key":"10.1016\/j.leukres.2020.106369_bib0075","article-title":"Toxicology of a novel small molecule ON 01910.NA on human bone marrow and leukemic cells in vitro","volume":"47","author":"Skidan","year":"2006","journal-title":"Proc. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.leukres.2020.106369_bib0080","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S0145-2126(15)30173-9","article-title":"Rigosertib, a novel RAS inhibitor, overcomes azacitidine resistance in acute myeloid leukemia cell lines","volume":"39","author":"Cosenza","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2020.106369_bib0085","article-title":"Rigosertib oral in transfusion dependent lower risk myelodysplastic syndromes (LR-MDS): optimization of dose and rate of transfusion independence (TI) or transfusion reduction (TR) in a single-arm phase 2 study","volume":"130","author":"Raza","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106369_bib0090","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106369_bib0095","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2020.106369_bib0100","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106369_bib0105","series-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. May 28","author":"U.S. Department of Health and Human Services","year":"2009"},{"issue":"4","key":"10.1016\/j.leukres.2020.106369_bib0110","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/bjh.12436","article-title":"Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes","volume":"162","author":"Komrokji","year":"2013","journal-title":"Br. J. Hematol."},{"key":"10.1016\/j.leukres.2020.106369_bib0115","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111756","article-title":"A randomized phase II study of azacitidine (AZA) alone or with lenalidomide (LEN) valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS: gfm\u2019s \u201cpick a winner\u201d trial","volume":"132","author":"Ades","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106369_bib0120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood.V122.21.386.386","article-title":"A phase II trial of epigenetic modulators vorinostat in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS): initial results of study 6898 of the New York Cancer Consortium","volume":"122","author":"Silverman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106369_bib0125","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/blood-2012-06-434639","article-title":"Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes","volume":"120","author":"Sekeres","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106369_bib0130","series-title":"VIDAZA\u00ae (Azacitidine for Injection) Prescribing Information","year":"2007"},{"key":"10.1016\/j.leukres.2020.106369_bib0135","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2147\/PPA.S106629","article-title":"Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature","volume":"10","author":"Eek","year":"2016","journal-title":"Patient Pref. Adherence"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:59:48Z","timestamp":1758934788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":27,"alternative-id":["S0145212620300746"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106369","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106369"}}